The Dermatological Spectrum of Coronavirus Disease-19 Disease: Cutaneous Signs for Diagnostics and Prognosis and an Expanded Classification

Uwe Wollina, Anca Chiriac, Ayse Serap Karadag

1Department of Dermatology and Allergology, Städtisches Klinikum Dresden, 01067 Dresden, Germany; 2Department of Dermatology, Apollonia University, Iasi, Romania; 3Division of Dermatology, Nicolina Medical Center, Iasi, Romania; 4“P. Poni” Institute of Macromolecular Chemistry, Romanian Academy, Iasi, Romania; 5Department of Dermatology, Istanbul Medeniyet University, Faculty of Medicine, Goztepe Research and Training Hospital, Istanbul, Turkey

Abstract

During severe acute respiratory syndrome coronavirus (CoV)-2- induced CoV disease (COVID-19) pandemic cutaneous signs of the disease gained increasing interest for early diagnosis, to establish a prognosis and for differential diagnoses. The present review aims to summarize current knowledge on cutaneous findings in COVID-19. The findings are classified and described clinically. The spectrum of cutaneous signs include acro-ischemic lesions, rash, chilblain-like eruptions, and androgenetic alopecia. Their significance is given, and treatment options are presented. This may allow the clinicians to support triage and optimal treatment for COVID-19 patients.

Key Bullets

- The COVID-19 pandemic has affected patients worldwide. Despite the leading symptoms are in the respiratory, cardiovascular, hematologic, and neurololgic systems, cutaneous manifestations are increasingly being observed.
- Cutaneous findings in COVID-19 patients may have prognostic and therapeutic consequences. This review attempts to classify cutaneous symptoms, document the observed frequency of their occurrence, the significance for triage of COVID-19 patients, and the treatment of cutaneous manifestations.

Introduction

The coronavirus (CoV) disease (COVID)-19 pandemic originated in Wuhan, China, and is caused by a new beta-CoV, named severe acute respiratory syndrome-CoV (SARS-CoV)-2 [1]. The virus enters host cells with the support of its surface spike proteins. Angiotensin-converting enzyme 2 (ACE2) has been identified as the entry receptor and employs the cellular serine protease TMPRSS2 for S protein priming [2]. Since ACE2 is regulated by androgens, this may contribute to the higher rate of males affected [3].

Infection can be from animals to humans and human-to-human. Among humans, the most common transmission is by respiratory droplets. The primary entry point is the respiratory system, although the virus can also infect the digestive, urinary, neurologic, and hematologic system. Other possible ways of transmission are fecal-oral and mother-to-child. Incubation time varies between 5 and 14 days, seldom longer [4].

Typical symptoms of infection by SARS-CoV-2 are fever, fatigue, dry cough, dyspnea, with or without nasal congestion, runny nose or other upper respiratory symptoms, lymphopenia, thrombocytopenia, and leukopenia. Patients may present with atypical symptoms such as headache, vomiting, diarrhea, and hemoptysis or stay asymptomatic [5, 6].

Complications include the acute respiratory distress syndrome, acute heart injury, stroke, encephalopathy, and secondary infections [5, 7, 8]. Patients older than 60 years and/or comorbidities are at higher risk for complications, hospitalization, and mortality. The rate of patients to be treated at the intensive care unit (ICU) varies from nearly 30% in the initial Wuhan epidemic to around 12% on northern Italy and 7% in Germany [9, 10, 11].
Distribution of SARS-CoV-2 in Human Tissues

Three autopsy cases from Chongqing, China, demonstrated by immunohistochemistry that alveolar epithelia and macrophages were partially positive for the 2019-nCoV antigen. Real-time -polymerase chain reaction (rT-PCR) analyses identified positive signals for 2019-nCoV nucleic acid [12]. In two autopsies from Cleveland/OH, USA, viral RNA was detected in lungs, bronchi, lymph nodes, and spleen using quantitative rT-PCR method on formalin-fixed paraffin-embedded tissue specimen [13]. Among 26 autopsy cases from Wuhan, China, immunostaining with SARS-CoV nucleoprotein antibody was positive in renal tubules [14]. In 12 patients who died from COVID-19 in Hamburg/ Germany, SARS-CoV-2 RNA was detected in the lung at high concentrations. Viremia in 6 of 10 and 5 of 12 patients demonstrated high viral RNA titers in the liver, kidney, or heart during autopsy [15]. In three autopsy cases from Zürich, Switzerland, presence of viral elements within endothelial cells and the induction of endothelitis in several organs as a direct consequence of viral involvement have been documented [16].

The expression of ACE2 was demonstrated in human skin samples using single-cell RNA sequencing. It was significantly higher in keratinocytes than other cell types in skin, such as fibroblasts and melanocytes. Immunostainings for ACE2 were positive in epidermal basal layer, stratum spinosum and stratum granulosum [17]. SARS-CoV-2, on the contrary, has not been detected in skin [12].

By the support of neuronal network possible conceptual associations from unstructured text and triangulation with insights from single cell RNA-sequencing (seq), bulk RNAseq and proteomics from diverse tissue types have been analyzed. It could be demonstrated that tongue keratinocytes, olfactory epithelial cells, airway club cells, and respiratory ciliated cells are potential reservoirs of the SARS-CoV-2 receptor. The gut was identified as the putative hotspot of COVID-19, where a maturation correlated transcriptional signature is shared in small intestine enterocytes among CoV receptors (ACE2 and others) [18].

Epidemiology of Cutaneous Manifestation of COVID-19

The initial trials from Wuhan suggested a low prevalence of 0.2% of any cutaneous findings among symptomatic patients [19]. The prevalence of cutaneous manifestations in uncontrolled trials and reports varies extremely from zero (Tibetan highland) to almost 100% (Thailand) [20].

There is a need for better epidemiological data on the subject. One initiative to improve data collection and analysis comes from the American Academy of Dermatology [21].

Classification of COVID-19-related Cutaneous Manifestations

A nationwide Spanish study among dermatologists included 375 COVID-19 cases with cutaneous manifestations. Based on this large data set, the authors tried to classify the cutaneous findings into five categories [22]:

- Asymmetrical distributed chilblain-like acral areas of erythema and/or edema with some vesicles or pustules (pseudo-chilblain) on digits hand and feet and heels
- Vesicular monomorphic eruptions (varicella-like)
- Urticarial lesions
- Maculopapular rash
- Acro-ischemic lesions (Livedo or necrosis).

We had like to add some more possible cutaneous findings:

1. Symmetrical flexural and intertriginous exanthema
2. Purpuric rash
3. Erythema multiforme-like rash and Kawasaki-like disease/multisystemic inflammatory syndrome in children (MIS-C)
4. Others (Molling, Sweet syndrome-like, pustulosis eruptions, and androgenetic alopecia [AGA]) (Table 1).

Table 1: Cutaneous signs of COVID-19, their frequency and significance

| Cutaneous signs | Frequency | Remarks | Significance |
|-----------------|-----------|---------|--------------|
| Cell | up to 19% | Mostly children | Mild or silent disease |
| Vesicular eruptions | 9–15% | Symptomatic adults | Could be a sign of a viral infection |
| Urticarial lesions | 1.4–19% | Often with pyrexia | In case of eosinophilia, the prognosis might be better |
| Acro-ischemic lesions | up to 47% | Mostly adults | Nonspecific, drug hypersensitivity should be excluded |
| Acro-ischemic lesions | Rare | Thromboembolic, DIC | Red flag for severe course, mortality is high |
| Purpuric rash | Unknown | Underestimated in developing countries | Exclude a drug reaction |
| EM | Rare | Unknown | Excluded |
| KD | Unknown | Children | Severe course, but often good prognosis |
| MIS-C | Unknown | Adults | Severe disease, ICU support |
| Molling | Unknown | Adults | Probably |
| SS-like | Unknown | Adults | hydroxychloroquine-induced mortality |
| Pustular eruptions | AGA | Adults | More severe course |

AGA: Androgenetic alopecia; CE: Chilblain-like eruptions; EM: Erythema multiforme; DIC: Diffuse intravascular coagulation; KD: Kawasaki disease; MIS-C: Multisystemic Inflammatory Syndrome in Children; SS-like: Sweet syndrome-like eruptions; SDRIFE-like: Symmetrical flexural and intertriginous exanthema.
Chilblain-like Acral Lesions

**Clinics**

Mostly asymmetrical distributed chilblain-like violaceous, infiltrated acral areas of erythema, and/or edema with some vesicles or pustules ("pseudo-chilblain") can be observed on hand and feet (Figure 1) [22]. Proximal nail fold capillaroscopy/dermoscopy remains normal [23].

![Figure 1: Asymmetric chilblain-like lesions. (a) Erythematous plaque on the antithenar. (b) Ill-defined infiltrations on two fingers. Nail fold capillaries are without abnormalities](image)

There is a number of case reports on chilblain-like lesions mainly in children and adolescents. Pruritus and (mild) burning pain are two equally distributed major symptoms [24], [25], [26]. In a series of 63 patients, there was no significant gender difference. The median age was 14 years and feet alone were mostly affected (85.7%), followed by feet/hands together (7%) and hands alone (6%). Asymptomatic lesions were present in 25.4% of cases [27].

**Frequency**

The nationwide Spanish study reported chilblain-like lesions in 19% of cases [22]. In a retrospective observational nationwide study among French private practices, 277 patients were enrolled with a median age of 27 years. Chilblain-like lesions were the most frequent acral lesions (n=106/142, 75%) [28].

In the rare cases with a lesional skin biopsy, vasculitis signs were noted in small to medium sized vessels with endothelial cell swelling and red blood cell extravasation. Fibrin thrombi was evident in superficial capillary vessels [29]. In an adult case, absence of significant papillary dermal edema was associated with a superficial and deep lymphoplasmacytic infiltrate, vacuolar interface dermatitis with some apoptotic keratinocytes and smudging of the basement membrane zone. The venules surrounded by the lymphoplasmacytic infiltrate had plump endothelial cells. Neither intraluminal fibrin thrombi nor venule wall fibrin deposits were detected. Direct immunofluorescence result was negative. Altogether these findings suggest a type I interferon response [30].

**Significance**

The percentage of patients with this type of cutaneous lesions tested positive for SARS-CoV-2 is between 15% (prospective study) and 25% (retrospective study). This raises questions, if the chilblain-like lesions are markers of COVID-19 [31]. Some authors recommend SARS-CoV-2 testing in children and adolescents with chilblain-like lesions to support early detection of silent carriers [32].

**Treatment**

In uncomplicated cases topical mometasone furoate and heparin gel for a few days is recommended [33].

Vesicular Monomorphic Eruptions

**Clinics**

Vesicular monomorphic eruptions on the trunk or the extremities, with possible hemorrhagic content have been observed mostly in symptomatic COVID-19 cases [22].

These lesions present initially as erythematous papules with a tendency to superficial vesiculation that eventually leads to crust formation. The presentation is varicella-like although most patients may be in good general health condition [34]. In a series of 22 patients from Northern Italy tested positive for SARS-Cov2, the median age was 60 years, and 72.7% of patients were male. The trunk as involved in all cases and the median time to remission was 8 days. Facial skin and mucosa were spared. Itch was noted in about 40% of patients [35].

**Frequency**

Vesicular monomorphic eruptions on the trunk or the extremities, with possible hemorrhagic content accounted for 9% of cases in the Spanish nationwide study [22]. In France, vesicular eruptions were observed in 41 outpatient cases (15%) [28].

**Significance**

The vesicular eruptions are considered probably COVID-19 specific, but vesicular drug-reactions and
other viral (co-)infections might contribute [36], [37]. Further studies are needed.

**Treatment**

These eruptions do not need any treatment, they can pass by itself. Wet dressing can be done to relieve the patient from itch. Topical antibacterial cream can be added if secondary impetiginization occurs.

**Urticarial Rash**

**Clinics**

Urticaria with wheals and flares is a non-specific cutaneous symptom in COVID-19 patients (Figure 2). Here, urticarial lesions occur mostly on the trunk, rarely palmar. Pyrexia with urticaria may be more characteristic than urticaria alone [22].

**Frequency**

Urticaria was observed in 19% of Spanish COVID-19 patients and in 1/14 in a French study [22], [26]. Among 140 hospitalized Chinese patients in Wuhan 1.4% self-reported urticarial [38]. A recent literature review reported urticaria in 9.7% of cases (7/72) [39].

**Significance**

In case of urticaria with eosinophils, theoretically a better outcome is possible [40]. Differential diagnoses include idiopathic urticaria, drug eruptions, and other viral infections with urticarial rash. If the patient is not taking medication and does not have idiopathic urticaria diagnosis, it is more likely to think of COVID-19 specific urticaria.

**Maculopapular Rash**

**Clinics**

Maculopapular rash is a non-specific cutaneous finding in COVID-19 patients (Figure 3). Lesions may show a possible perifollicular distribution. Variants were described as pityriasis rosea-like with a variable degree of purpuric areas or erythema elevatum diutinum-like. The rash lasts on average 9 days. It is uncommon among children affected by COVID-19 [20].

**Frequency**

In the Spanish trial maculopapular rash was a common cutaneous finding observed in 47% of cases [22]. Face and palmoplantar skin is usually spared. Histologic and clinical presentation is not uniform. If needed, symptomatic topical treatment with corticosteroids and oral antihistamines can be used [20].

**Significance**

Maculopapular rash is a non-specific cutaneous finding in COVID-19. The most important differential diagnosis is drug-induced exanthema.
**Treatment**
Symptomatic treatment with oral antihistamines and topical corticosteroids is an option.

**Acro-ischemic Lesion (Livedo or Necrosis)**

**Clinics**
Transient livedo reticulans-like lesions have occasionally been observed in symptomatic COVID-19 patients. The livedoid changes may be unilateral in nature. They can eventually result in skin necrosis. The lesions are thought to be secondary to SARS-CoV-2-induced thrombotic vasculopathy [22], [26]. Acro-ischemia presenting with finger and toe cyanosis, skin bullae, and dry gangrene are a red-flag sign for severe illness (Figure 4).

![Figure 4: Acro-ischemic ulcerations. (a) Transitory livedoid erythema. (b) Ulcerated papule. Disseminated ulcerated papules may be a sign of DIC. (c) Two neighboring ulcerations on the foot. (d) Ulcerated lesion on the heel.](image)

**Frequency**
The frequency of livedo and necrosis was 6% in Spain and 2.8% in a recent literature review [22], [39].

**Significance**
If livedoid and necrotic eruptions occur in COVID-19 patients, this could be a clue for systemic thrombotic vasculopathy. It will be particularly important to recognize the eruptions clinically, since they may have (strong negative) prognostic value in these patients.

It is important to separate acral lesions in the elderly from chilblain-like eruptions in youngsters since these could have a necrotic outcome [43]. Acro-ischemia presentations are associated with severe COVID-19 disease and high mortality [44].

**Treatment**
Treatment is dependent on underlying pathology (acral ischemia, and disseminated intravascular coagulopathy [DIC]). In the initial phase of the SARS-CoV-2 infection, D-dimer and fibrinogen levels are increased, while prothrombin time, activated partial prothrombin time, and platelet counts are often normal. Diagnosis of DIC needs laboratory evaluation of soluble fibrin, protein C, and plasminogen activator inhibitor 1.

For hospitalized COVID-19 patients, thromboprophylaxis using low-molecular-weight heparin is recommended [45]. Recombinant human soluble thrombomodulin has proven clinically useful for treating DIC leading to a higher resolution rate after 7 days of application [46]. Adjuvant plasmapheresis has been used occasionally in DIC [47].

**Symmetrical Flexural and Intertriginous Exanthema**

**Clinics**
Symmetrical flexural and intertriginous exanthema are a rare manifestation of COVID-19. It resembles clinically Symmetrical Drug-Related Intertriginous and Flexural Exanthema (SDRIFE).

**Frequency**
This symptom has been seen in single cases several days after the COVID-19 fever developed [48].

**Significance**
Drug-induced SDRIFE needs to be excluded before the diagnosis of COVID-19 SDRIFE can be made.

**Treatment**
Symmetrical flexural and intertriginous exanthema is temporary. In one case, it disappeared after 18 days without any specific treatment [48].
Purpuric Rash

Clinics
Acute undifferentiated febrile illness is one of the initial presentations of COVID-19. Purpuric rash in COVID-19 may resemble other viral rashes like dengue fever [49], [50]. Very rare is Schamberg's-like purpura in mild COVID-19 [51].

Frequency
The frequency is obviously dramatically underestimated in tropical countries [52].

Significance
In hotspots of arboviral diseases, these disorders need to be excluded [53]. On the other hand, SARS-CoV-2 and dengue fever have been reported as coinfections from various developing countries [54], [55], [41].

Treatment
Antipyretics and topical corticosteroids can be combined.

Erythema Multiforme-like Rash and Kawasaki-like Disease/MIS-C

Clinics
Four female hospitalized COVID-19 patients in Madrid, Spain, presented an erythema multiforme-like rash. The mean age was 66.8 years. The mean time between onset of COVID-19 to the appearance of erythematous lesions was 19.5 days. Three patients developed the rash 4–7 days after clinical improvement with negative COVID-19 PCR test. These lesions developed from erythematous papules on the upper trunk that progressively turned into targetoid erythematous or violaceous patches with a dusky center, and a pseudo-vesicle in the middle. They spread to the face and limbs within 1 week, but spared palms and soles. Oral mucosa was also involved with palatal macules and petechiae. Histological examination showed dilated dermal vessels filled with neutrophils, extravasation of red blood cells, and lymphocytic perivascular and interstitial infiltrate [41]. One case report from France described a 6-year-old boy with erythema multiforme-like mucocutaneous lesions [56].

A prospective observational study from Paris, France, reported on 14 children with COVID-19 and Kawasaki-like disease. Almost 60% originated from sub-Saharan Africa or Caribbean islands. All children had marked gastrointestinal symptoms and high levels of inflammatory markers. Eleven patients presented with Kawasaki disease (KD) shock syndrome requiring ICU support, and 12 suffered from myocarditis [57]. Kawasaki-like eruptions including generalized exanthema, cheilitis, stomatitis, and bilateral conjunctivitis, bilateral palmar edema, glossitis, and cervical lymphadenopathy had been reported in a 3-year-old boy. Cutaneous desquamation of the extremities was noted later on [56]. A 6-year-old girl with rT-PCR confirmed COVID-19 met criteria for incomplete KD, including fever for more than 7 days with conjunctivitis, rash, edema of the hands and feet, elevated CRP and erythrocyte sedimentation rate, hypoaalbuminemia, anemia, and 2-D echocardiogram findings suggestive of myocarditis [58].

An important differential diagnosis of Kawasaki-like disease is MIS-C. MIS-C is characterized by (1) prominent cardiac dysfunction with troponin leak and extremely elevated brain natriuretic peptide, (2) frequent and often severe enteropathy, and (3) relative thrombocytopenia. In some patients, fever and gastrointestinal symptoms precede the classical KD features such as cutaneous rash, conjunctivitis, mucous membrane changes, and extremity edema [59].

Frequency
One series of 17 children and several case reports have been published so far [41], [56], [57], [60], [61].

Significance
Other viral (co-) infections such as parvovirus B19 and herpes simplex have to be excluded. Kawasaki-like disease often needs ICU support for affected children.

Treatment
If necessary, oral corticosteroids may be given temporary for erythema multiforme-like eruptions. In case of Kawasaki-like disease, intravenous immunoglobulins at 2 g/kg, systemic corticosteroids, and aspirin have been recommended [57], [61].

Other Cutaneous Findings

Mottling
A 15-day-old neonate of a SARS-CoV-2 positive mother developed COVID-19 without cough.
The cutaneous findings were described as mottling. The newborn was isolated and subjected to supportive care. Antibiotic and antiviral treatment was initiated. The outcome was complete remission after 6 days [58].

**Sweet syndrome-like eruptions**

A 61-year-old woman without respiratory symptoms but fever, fatigue, arthralgia, and myalgia, was admitted to a hospital in Istanbul, Turkey. On examination, she presented numerous erythematous nodules on the cheeks, scalp, extremities, and the trunk. Minor aphthous ulcers were observed on the hard palate and buccal mucosa. Thoracic computerized tomography presented multifocal ground-glass opacities. The laboratory was remarkable for leukocytosis, neutrophilia, and mild lymphopenia, C-reactive protein was elevated with 78.2 (<5.0 mg/L). Although an initial SARS-CoV-2 rT-PCR was negative, a repeated test became positive. A skin biopsy from the elbow revealed a diffuse neutrophilic infiltration in the upper dermis and vascular proliferations with swollen endothelial cells and extravasated erythrocytes. In the lower dermis and at the periphery of the lobules of subcutaneous fat tissue, there were granulomas, composed of epithelioid histiocytes and multinuclear giant cells and other inflammatory cells. Clinical and histopathological features were considered as erythema nodosum-like Sweet syndrome [62]. Another case is shown in Figure 5.

![Figure 5: Sweet-like plaques and pustules on the arms](image)

**Pustular rash**

A 69-year-old woman from Madrid, Spain, with confirmed COVID-19 disease developed a pustular rash resembling acute exanthematous pustulosis 33 days after onset of COVID-19 symptoms. Histology revealed subcorneal pustulosis, spongiosis, papillary edema, and discrete neutrophilic inflammatory infiltrate [63]. Several other cases have been reported in adult COVID-19 patients [64], [65]. Since these patients were treated with hydroxychloroquine, a delayed drug-reaction is possible [66]. A direct effect of SARS-CoV-2 remains unproven (Figure 6).

![Figure 6: Acute exanthematic pustulosis due to hydroxychloroquine treatment of COVID-19](image)

**AGA; Gabrin sign**

AGA severity reflects the androgen activity over age. Among 175 confirmed and hospitalized COVID-19 patients in Spain, 122 were males and 53 were females. AGA was present in 67% of the patients, 70 patients presented with clinically relevant AGA. The frequency of AGA was 79% in males and 42% in females. The prevalence of age matched males in a similar Caucasian population was estimated to be 31–53%, in females >70 years and the prevalence reported was 38% [67]. This argues for a significantly higher rate of AGA at least in COVID-19 positive males. Furthermore, it seems to be a marker for a more severe course of COVID-19 [68].

Dr. Gabrin was the first physician to die from COVID-19 in the US and suffering from AGA. Therefore, the eponym “Gabrin sign” has been proposed for AGA in COVID-19 patients [67].

**Conclusions**

During the COVID-19 pandemic dermatologists play an active role in patients’ triage, in early diagnosis of cutaneous signs, in the recognition of cutaneous red-flags for an unfortunate course of the disease. Their active participation is necessary to record cutaneous findings, to confirm diagnoses and make the necessary differential diagnostic procedures [69]. The most important diseases to be considered are tropical and other viral disorders and drug hypersensitivities. However, we are still at the beginning and should be aware of unexpected findings.

**References**

1. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A novel coronavirus from patients with pneumonia in China, 2019. N
Engl J Med. 2020;382(8):727-33. PMid:31978945

2. Cevik M, Bamford CG, Ho A. COVID-19 pandemic—a focused review for clinicians. Clin Microbiol Infect. 2020;6(7):842-7.

3. De Toni L, Garolla A, Di Nisio A, Rocca MS, Foresta C. Caution in the management of SARS-CoV-2 infection in males. Andrology. 2020;2020:12829. https://doi.org/10.1016/andr.12829

4. Wu D, Wu T, Liu Q, Yang Z. The SARS-CoV-2 outbreak: What we know. Int J Infect Dis. 2020;94:44-8. PMid:32171952

5. Huang C, Wang Y, Li X, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497-506. https://doi.org/10.1016/s0140-6736(20)30183-5

6. Holshue ML, DeBolt C, Lindquist S, Lofy KH, Wiesman J, et al. First case of 2019 novel coronavirus in the United States. N Engl J Med. 2020;382(10):929-36. PMid:32004427

7. Hess DC, Eldahshan W, Rutkowski E. COVID-19-related stroke. Transl Stroke Res. 2020;11(3):322-5. https://doi.org/10.1007/s12975-020-00818-9

8. Long B, Brady WJ, Koyfman A, Gottlieb M. Cardiovascular complications in COVID-19. Am J Emerg Med. 2020;38(7):1504-7. PMid:32171952

9. Wu D, Wu T, Liu Q, Yang Z. The SARS-CoV-2 outbreak: What we know. Int J Infect Dis. 2020;94:44-8. PMid:32171952

10. Grasselli G, Pesenti A, Cecconi M. Critical care utilization for COVID-19 cases. Am J Clin Pathol. 2020;154(2):190-200. https://doi.org/10.1093/ajcp/aqaa091

11. World Health Organization. Preliminary Assessment of the Severity of COVID-19 in Germany Based on the Transmitted Cases According to German Infection Protection Act. Geneva, Switzerland: World Health Organization; 2020.

12. Yao XH, Li TY, He ZC, Ping YF, Liu HW, Yu SC, et al. Classification of the cutaneous manifestations of COVID-19: A rapid prospective nationwide consensus study in Spain with 375 cases. Br J Dermatol. 2020;183(1):71-7. https://doi.org/10.1111/bjd.18163 PMid:32348545

13. olivras A, Devay F, Delplace D, Feoli F, Meiers I, Milone L, et al. Coronavirus (COVID-19) infection-induced chilblains: A case report with histopathological findings. JAD Case Rep. 2020;6(6):489-92. https://doi.org/10.1016/j.jdar.2020.04.011 PMid:32363225

14. Landa N, Mendieta-Eckert M, Fonda-Pascual P, Aguirre T. Chilblain-like lesions on feet and hands during the COVID-19 Pandemic. Int J Dermatol. 2020;59(7):739-43. https://doi.org/10.1111/ijd.14937 PMid:32329897

15. Andina D, Nogueira-Morel L, Bascuas-Arribas M, Gaiteiro-Tristán J, Alonso-Cadenas JA, Escalada-Pellitero S, et al. Chilblains in children in the setting of COVID-19 pandemic. Pediatr Dermatol. 2020;37(3):406-11. https://doi.org/10.1111/pde.14215 PMid:32386460

16. Bouaziz JD, Duong T, Jacquet M, Velter C, Lestang P, Cassius C, et al. Vascular skin symptoms in COVID-19: A French observational study. J Eur Acad Dermatol Venereol. 2020;2020:12829. https://doi.org/10.1111/andr.12829

17. Xue X, Mi Z, Wang Z, Pang Z, Liu H, Zhang F. High expression of ACE2 on the keratinocytes reveals skin as a potential target for SARS-CoV-2. J Invest Dermatol. 2020;2020:87. https://doi.org/10.1016/j.jid.2020.05.087 PMid:32454066

18. Venkatakrishnan AJ, Puranik A, Anand A, Zemmour D, Yao X, Wu X, et al. Knowledge synthesis of 100 million biomedical documents augments the deep expression profiling of coronavirus receptors. Elife. 2020;9:e58040. https://doi.org/10.7554/elife.58040 PMid:32463365

19. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382(18):1708-20.

20. Wollina U, Karadag AS, Rowland-Payne C, Chiriac A, Lotti T. Chilblain-like lesions in children following suspected COVID-19 infection. Pediatr Dermatol. 2020;37(3):406-11. https://doi.org/10.1111/pde.14215 PMid:32386460

21. Freeman EE, McMahon DE, Fitzgerald ME, Fox LP, Rosenbach M, Takeshita J, et al. The AAD COVID-19 Registry: Crowdsourcing Dermatology in the Age of COVID-19. J Am Acad Dermatol. 2020;83(2):509-10. https://doi.org/10.1016/j.jaad.2020.04.045 PMid:32305438

22. Galván Casas C, Catalá A, Hernández GC, Rodríguez-Jiménez R, Fernández-Nieto D, Lario AR, et al. The AAD COVID-19 Registry: Crowdsourcing Dermatology in the Age of COVID-19. J Am Acad Dermatol. 2020;83(2):509-10. https://doi.org/10.1016/j.jaad.2020.04.045 PMid:32305438

23. Andina D, Nogueira-Morel L, Bascuas-Arribas M, Gaiteiro-Tristán J, Alonso-Cadenas JA, Escalada-Pellitero S, et al. Chilblains in children in the setting of COVID-19 pandemic. Pediatr Dermatol. 2020;37(3):406-11. https://doi.org/10.1111/pde.14215 PMid:32386460

24. Bouaziz JD, Duong T, Jacquet M, Velter C, Lestang P, Cassius C, et al. Vascular skin symptoms in COVID-19: A French observational study. J Eur Acad Dermatol Venereol. 2020;2020:12829. https://doi.org/10.1111/andr.12829

25. Andina D, Nogueira-Morel L, Bascuas-Arribas M, Gaiteiro-Tristán J, Alonso-Cadenas JA, Escalada-Pellitero S, et al. Chilblains in children in the setting of COVID-19 pandemic. Pediatr Dermatol. 2020;37(3):406-11. https://doi.org/10.1111/pde.14215 PMid:32386460

26. Bouaziz JD, Duong T, Jacquet M, Velter C, Lestang P, Cassius C, et al. Vascular skin symptoms in COVID-19: A French observational study. J Eur Acad Dermatol Venereol. 2020;2020:12829. https://doi.org/10.1111/andr.12829

27. Piccolo V, Neri I, Filippeschi C, Oranges T, Argenziano G, et al. Endothelial cell infection and endotheliitis during the COVID-19 pandemic: A retrospective nationwide study from France. J Am Acad Dermatol. 2020;37(3):437-41.
30. Docampo-Simón A, Sánchez-Pujol MJ, Juan-Carpena G, Palazón-Cabanes JC, Vergara-De Caso E, Berbegal L, et al. Are chilblain-like acral skin lesions really indicative of COVID-19? A prospective study and literature review. J Eur Acad Dermatol Venereol. 2020;37(3):435-6. https://doi.org/10.1111/jdv.16665

31. Genovese G, Colonna C, Marzano AV. Varicella-like exanthem associated with COVID-19 in an 8-year-old girl: A diagnostic clue? Pediatr Dermatol. 2020;37(3):435-6. https://doi.org/10.1111/pde.14201

32. Marzano AV, Genovese G, Fabbrocini G, Pigato P, Monfrecola G, Piraccini BM, et al. Varicella-like exanthem as a specific COVID-19-associated skin manifestation: Multicenter case series of 22 patients. J Am Acad Dermatol. 2020;83(1):280-5. https://doi.org/10.1016/j.jaad.2020.05.072

33. Ortega-Oquiñano D, Jimenez-Cauhe J, Burgos-Blasco P, Jimenez-Gomez N, Fernandez-Nieto D. Reply to “Varicella-like exanthem as a specific COVID-19-associated skin manifestation: multicenter case series of 22 patients”: Discussing specificity. J Am Acad Dermatol. 2020;83(1):e87. https://doi.org/10.1016/j.jaad.2020.04.156

34. Llamas-Velasco M, Rodriguez-Jiménez P, Chicharro P, De Argila D, Muñoz-Hernández P, Daudén E. Reply to “Varicella-like exanthem as a specific COVID-19-associated skin manifestation: Multicenter case series of 22 patients”: To consider varicella-like exanthem associated with COVID-19, virus varicella zoster and virus herpes simplex must be ruled out. J Am Acad Dermatol. 2020;2020:30943-9. https://doi.org/10.1016/j.jaad.2020.04.180

35. Bouaziz JD, Duong T, Jachiet M, Velter C, Lestang P, Bouaziz JD, Duong T, Jachiet M, Velter C, Lestang P, et al. Multicenter clinical experience with recombinant soluble thrombomodulin for disseminated intravascular coagulation associated with severe acute cholecystitis. Thromb Res. 2019;176:74-8. https://doi.org/10.1016/j.thromres.2018.12.025

36. Upadhyay SR, Mahabala C, Kamat JG, Jeganathan J, Kumar S, Prabhu MV. Plasmapheresis in sepsis-induced thrombotic microangiopathy: A case series. Indian J Crit Care Med. 2020;24(3):195-9. https://doi.org/10.4269/ajtmh.20-0440

37. Rajasekharan N, Prasun S, Sayin S, Sivasubramanian S, Hanselman DS, Thomas D. Acute cholecystitis associated with COVID-19: Clinical and histological findings. Clin Exp Dermatol. 2020;2020:14281. https://doi.org/10.1111/ced.14281

38. Ehsani AH, Nasimi M, Bigdeli Z. Pityriasis rosea as a cutaneous manifestation of COVID-19 infection. J Eur Acad Dermatol Venereol. 2020;2020:16579. https://doi.org/10.1111/jdv.16579

39. Balestri R, Termine S, Rech G, Girardelli CR. Late onset of acral necrosis after SARS-CoV-2 infection resolution. J Eur Acad Dermatol Venereol. 2020;2020:16668. https://doi.org/10.1111/jdv.16668

40. Zhang JY, Cao W, Xiao M, Li YJ, Yang Y, Zhao J, et al. Clinical and Coagulation Characteristics in 7 Patients With Critical COVID-19 Pneumonia and Acro-Ichaeism. Zhonghua Xue Ye Xue Za Zhi. 2020;41(4):302-7.

41. Navarro JC, Arribillaga-Henríquez J, Salazar-Loor J, et al. Multicentric case series of 22 patients: Varicella-like exanthem as a specific COVID-19-associated skin manifestation: Multicenter case series of 22 patients. J Am Acad Dermatol. 2020;83(1):280-5. https://doi.org/10.1016/j.jaad.2020.05.072
Rodriguez-Morales AJ. COVID-19 and dengue, co-epidemics in Ecuador and other countries in Latin America: Pushing strained health care systems over the edge. Travel Med Infect Dis. 2020;2020:101656. https://doi.org/10.1016/j.tmaid.2020.101656
PMid:32268196

Yan G, Lee CK, Lam LT, Yan B, Chua YK, Lim AY, et al. Covert COVID-19 and false-positive dengue serology in Singapore. Lancet Infect Dis. 2020;20(6):536. https://doi.org/10.1016/s1473-3099(20)30158-4
PMid:32145189

Labé P, Ly A, Sin C, Nasser M, Chapelon-Fromont E, Ben Saïd P, et al. Erythema multiforme and Kawasaki disease associated with COVID-19 infection in children. J Eur Acad Dermatol Venereol. 2020;2020:16666. https://doi.org/10.1111/jdv.16666
PMid:32455505

Toubiana J, Poirault C, Corsia A, Bajolle F, Fourgeaud J, Angoulvant F, et al. Outbreak of Kawasaki disease in children during COVID-19 pandemic: A prospective observational study in Paris, France. BMJ. 2020;369:m2094. https://doi.org/10.1136/bmj.m2094
PMid:32493739

Kamali Aghdam M, Jafari N, Effekhari K. Novel coronavirus in a 15-day-old neonate with clinical signs of sepsis, a case report. Infect Dis (Lond). 2020;52(6):427-9. https://doi.org/10.1080/23744235.2020.1747634
PMid:32233816

Chiotos K, Bassiri H, Behrens EM, Blatz AM, Chang J, Diorio C, et al. Multisystem Inflammatory Syndrome in Children during the COVID-19 pandemic: A case series. J Pediatric Infect Dis Soc. 2020;2020:piaa069. https://doi.org/10.1093/jpids/piaa069
PMid:32463092

Janah H, Zinebi A, Elbenayy J. Atypical erythema multiforme palmar plaques lesions due to Sars-Cov-2. J Eur Acad Dermatol Venereol. 2020;2020:174623. https://doi.org/10.1111/jdv.16623
PMid:32386446

Deza Leon MP, Redzapči A, McGrath E, Abdel-Haqq N, Shawaqfeh A, Sethuraman U, et al. COVID-19 associated pediatric multi-system inflammatory syndrome. J Pediatr Infect Dis Soc. 2020;9(3):407-8. https://doi.org/10.1093/jpids/piaa061
PMid:32441749

Taşkın B, Vural S, Altuğ E, Demirkesen C, Kocatürk E, Çelebi I, et al. COVID-19 Presenting with atypical sweet’s syndrome. J Eur Acad Dermatol Venereol. 2020;2020:16662. https://doi.org/10.1111/jdv.16662
PMid:32452542

Herrero-Moyano M, Capusan TM, Andreu-Varasoain M, Alcántara-González J, Ruano-Del Salado M, Uceda ME, et al. A clinicopathological study of 8 patients with COVID-19 pneumonia and a late-onset exanthema. J Eur Acad Dermatol Venereol. 2020;2020:16631. https://doi.org/10.1111/jdv.16631
PMid:32426864

Robustelli Test E, Vezzoli P, Carugno A, Raponi F, Gianatti F, Rongioletti F, et al. Acute generalized exanthematous pustulosis with erythema multiforme-like lesions in a COVID-19 woman. J Eur Acad Dermatol Venereol. 2020;2020:16613. https://doi.org/10.1111/jdv.16613
PMid:32386448

Litaiem N, Hajlaoui K, Karray M, Slouma M, Zeglaoui F. Acute generalized exanthematous pustulosis after COVID-19 treatment with hydroxychloroquine. Dermatol Ther. 2020;2020:e13565. https://doi.org/10.1111/dth.13565
PMid:32401410

Schwartz RA, Janniger CK. Generalized pustular figurate erythema: A newly delineated severe cutaneous drug reaction linked with hydroxychloroquine. Dermatol Ther. 2020;2020:e13380. https://doi.org/10.1111/dth.13380
PMid:32253799

Wambier CG, Vaño-Galván S, McCoy J, Gomez-Zubiaur A, Herrera S, Hermosa-Gelbard A, et al. Androgenetic alopecia present in the majority of hospitalized COVID-19 patients the “gabrin sign”. J Am Acad Dermatol. 2020;83(2):680-2. https://doi.org/10.1016/j.jaad.2020.05.079
PMid:32446821

Goren A, Vaño-Galván S, Wambier CG, McCoy J, Gomez-Zubiaur A, Moreno-Arrones OM, et al. A preliminary observation: Male pattern hair loss among hospitalized COVID-19 patients in Spain a potential clue to the role of androgens in COVID-19 severity. J Cosmet Dermatol. 2020;19(7):1545-7. https://doi.org/10.1111/jocd.13443
PMid:32301221

Wollina U. Challenges of COVID-19 pandemic for dermatology. Dermatol Ther. 2020;2020:e13430.
PMid:32314460